NCT06079294 Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
| NCT ID | NCT06079294 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Autoimmune Encephalitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2024-05-31 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 56 participants in total. It began in 2024-05-31 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological syndromes criteria - at the acute phase, before immunomodulating treatment, or within 10 days of treatment initiation.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * Newly diagnosed autoimmune encephalitis based on at least 1 of the 3 following criteria : 1. " Definite limbic autoimmune encephalitis " according to 2016 Graus et al. criteria 2. " Possible autoimmune encephalitis " according to 2016 Graus et al. criteria AND typical autoantibody detected in serum or CSF 3. " Probable or certain paraneoplastic neurological syndrome " according to Graus et al. 2021 criteria (excluding peripheral neurological syndromes) * Less than 6 months since first neurological symptoms imputable to autoimmune encephalitis * Affiliated or entitled to a social security system (except AME) * Obtaining free, written and informed consent (patient or legal representative or the close relative) Exclusion criteria * History of brain tumor, head trauma, infarction or cerebral hematoma likely to result in altered cerebral carbohydrate metabolism on PET * Patients who hae been on immunotherapy (corticosteroid bolus, IVIg, plasma exchange, endoxan, rituximab or other immunotherapy) fr more than 10 days * Pregnant or breast-feeding woman * Ventilated intubated patient * Absolute contraindication to MRI (Pacemaker, cochlear implant, etc.) * Presence of cognitive disorders incompatible with goog cooperation with the PET scan * Algic or agitated patient unable to remain immobile in supine position for 30 minutes * Deprived of liberty or under a protective measure (guardianship or curatorship) * Patient taking part in other interventional research involving radiopharmaceutical injections
Contact & Investigator
Aurélie Kas, Pr
PRINCIPAL INVESTIGATOR
Hôpital Pitié Salpêtrière - Assistance Publique Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT06079294 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Autoimmune Encephalitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06079294 currently recruiting?
Yes, NCT06079294 is actively recruiting participants. Contact the research team at aurelie.kas@aphp.fr for enrollment information.
Where is the NCT06079294 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06079294 clinical trial?
NCT06079294 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Aurélie Kas, Pr at Hôpital Pitié Salpêtrière - Assistance Publique Hôpitaux de Paris. The trial plans to enroll 56 participants.